Generic placeholder image

Current Drug Research Reviews

Editor-in-Chief

ISSN (Print): 2589-9775
ISSN (Online): 2589-9783

Mini-Review Article

A Hidden Pandemic? Abuse of Gabapentinoids: A Brief Review of Recent Studies

In Press, (this is not the final "Version of Record"). Available online 28 November, 2023
Author(s): Gamze Zengin İspir*, Mustafa Danışman and Kübra Sezer Katar
Published on: 28 November, 2023

DOI: 10.2174/0125899775268780231002064605

Price: $95

conference banner
Abstract

Background: Gabapentin and pregabalin were developed for epilepsy and neuropathic pain. They work via voltage-gated calcium channels and are used for broad-spectrum diagnoses, e.g., epilepsy, neuropathic pain, other chronic pain syndromes, anxiety disorders, alcohol-drug withdrawal syndromes, agitation, insomnia, etc. Especially in a world dealing with the opioid crisis, gabapentinoids were considered safer alternatives to opioid analgesics.

Methods: This review aims to comprehensively search and summarize recent studies concerning the abuse of gabapentinoids published between 2021 and 2022 from various regions around the world.

Results: Studies have highlighted that a history of substance use disorder is a significant risk factor for gabapentinoid abuse. Concurrent abuse of gabapentinoids with illicit drugs can exacerbate drug-related damages. Drug screening and postmortem toxicology tests have revealed an increase in gabapentinoid consumption. In response to the abuse potential, several countries have classified gabapentinoids as controlled substances.

Conclusion: Gabapentinoids are highly abused molecules worldwide. Physicians should be aware of their abuse potential.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy